Abstract
Thirty-eight novel Pyrido-[2,3-d]-pyrimidin-2-amine derivatives (P1-P38) were designed, synthesized, and their structures confirmed using analytical techniques viz.,1H NMR, 13C NMR, and mass spectrometry. Using the Microplate Alamar Blue Assay (MABA), the final derivatives, P1-P38, were tested for their anti-mycobacterial activity against the Mycobacterium tuberculosis (Mtb) H37Rv strain. Amongst all the assessed compounds, P35 displayed significant inhibition with MIC 7.18 μg/mL. The remaining compounds exhibited MIC from 18.11 to >100 μg/mL. The potent compounds with MIC 〈 40.96 μg/mL, were evaluated for toxicity on HEK293T a normal human embryonic kidney cell line. The most active compound P35 exhibited a selectivity index 〉 20, proving its selective behavior towards Mtb H37Rv strain than human cells. To further evaluate the binding pattern in the active site of Thymidylate Kinase (TMPK) from Mtb (PDB-1G3U), a molecular docking analysis of compound P35 was performed using the glide module of Schrodinger software. Finally, molecular dynamics simulations were performed for 100 ns in order to elucidate the stability, confirmation, and intermolecular interactions of the co-crystal ligand and significantly active compound P35 on the selected target protein.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.